AI assistant
Moleculin Biotech, Inc. — Director's Dealing 2025
Nov 14, 2025
34881_dirs_2025-11-14_fa578a4d-6a10-4a74-873e-887e096ceb69.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Moleculin Biotech, Inc. (MBRX)
CIK: 0001659617
Period of Report: 2025-11-12
Reporting Person: Foster Jonathan P. (EVP & CFO)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-11-12 | Stock option (right to buy) | $0.49 | A | 600000 | Acquired | 2035-11-12 | Common Stock (600000) | Direct |
| 2025-11-12 | Performance Based Restricted Stock Units | $ | A | 400000 | Acquired | 2035-11-12 | Common Stock (400000) | Direct |
Footnotes
F1: The stock option set forth in this table vests in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date.
F2: Issued in connection with the reporting person's employment with the Company.
F3: Each restricted stock unit represents a contingent right to receive one shares of Company common stock.
F4: On November 12, 2025, the Board approved this performance based restricted stock unit. The performance based restricted stock units set forth in this table will vest in 20% installments upon the achievement of certain clinical milestones; provided that upon a change of control (as defined in the 2024 Stock Plan) 100% shall vest.